Evidence map›Paper›PMID 35358703›Full record

ArticleNeurobiology of disease2022

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease.

Jeremy F Strain, Nicolas Barthelemy, Kanta Horie, Brian A Gordon, Collin Kilgore, Andrew Aschenbrenner, Carlos Cruchaga, Chengjie Xiong, Nelly Joseph-Mathurin, Jason Hassenstab and 19 more

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 5 countries.

Jeremy F StrainDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Nicolas BarthelemyDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Kanta HorieDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Brian A GordonDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA; Department of Psychological & Brain Sciences, Washington University, St. Louis, MO 63110, USA.
Collin KilgoreDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Andrew AschenbrennerDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Carlos CruchagaDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Chengjie XiongKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA; Osaka City University School of Medicine Asahimachi, Abenoku, Osaka 545-8585, Japan.
Nelly Joseph-MathurinDepartment of Radiology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
Jason HassenstabDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA; Osaka City University School of Medicine Asahimachi, Abenoku, Osaka 545-8585, Japan.
Anne M FaganDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
Yan LiDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Celeste M KarchDepartment of Radiology, Washington University, St. Louis, MO 63110, USA.
Richard J PerrinDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Sarah B BermanDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Jasmeer P ChhatwalDepartment of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Hiroshi MoriOsaka City University School of Medicine Asahimachi, Abenoku, Osaka 545-8585, Japan.
Johannes LevinGerman Center for Neurodegenerative Disease (DZNE) Munich, Munich, Germany.
James M NobleDepartment of Neurology, Columbia University, New York, NY 100310, USA.
Ricardo AllegriSchool of Medicine, Universidad de Buenos Aires, Viamonte 430, C1053 CABA, Argentina.
Peter R SchofieldNeuroscience Research Australia, Sydney, NSW, Australia; Hope Center for Neurological Disorders, Washington University, St. Louis, MO 63100, USA.
Daniel S MarcusKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
David M HoltzmanDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
John C MorrisDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
Tammie L S BenzingerDepartment of Radiology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
Eric M McDadeDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Randall J BatemanDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.
Beau M AncesDepartment of Neurology, Washington University, St. Louis, MO 63110, USA; Department of Radiology, Washington University, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA. Electronic address: bances@wustl.edu.
Washington University in St. Louis · USOsaka City University · JPColumbia University · USGerman Center for Neurodegenerative Diseases · DEMassachusetts General Hospital · USMayo Clinic in Florida · USNeuroscience Research Australia · AUUniversity of Buenos Aires · ARUniversity of Pittsburgh · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Franklin Teich · 2020 to 2026
$30.1M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
THE XNAT IMAGING INFORMATICS PLATFORMR01EB009352 · NIBIB · WASHINGTON UNIVERSITY · PI Daniel Scott Marcus · 2009 to 2026
$9.3M
proj 3 - NINDS INSTIUTIONAL CENTER CORE GRANTS TO SUPPORT NEUROSCIENCE RESEARP30NS048056 · NINDS · WASHINGTON UNIVERSITY · PI MARCUS, DANIEL SCOTT · 2004 to 2014
$7.4M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2008 to 2009
$6.1M
Department of HealthMedical Research Council MR/009076/1Medical Research Council MR/L023784/1NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NIA NIH HHS K01 AG053474NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG052550NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIBIB NIH HHS R01 EB009352NINDS NIH HHS P30 NS048056NINDS NIH HHS P30 NS098577NINR NIH HHS R01 NR012657NINR NIH HHS R01 NR012907NINR NIH HHS R01 NR014449
6 · The paper itself

Abstract

backgroundHyperphosphorylation of tau leads to conformational changes that destabilize microtubules and hinder axonal transport in Alzheimer's disease (AD). However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s).

methodsIn autosomal dominant AD (ADAD) mutation carriers (MC) and non-carriers (NC) we compared cerebrospinal fluid (CSF) phosphorylation at tau sites (pT217, pT181, pS202, and pT205) and total tau with WM measures, as derived from diffusion tensor imaging (DTI), and cognition. A WM composite metric, derived from a principal component analysis, was used to identify spatial decline seen in ADAD.

resultsThe WM composite explained over 70% of the variance in MC. WM regions that strongly contributed to the spatial topography were located in callosal and cingulate regions. Loss of integrity within the WM composite was strongly associated with AD progression in MC as defined by the estimated years to onset (EYO) and cognitive decline. A linear regression demonstrated that amyloid, gray matter atrophy and phosphorylation at CSF tau site pT205 each uniquely explained a reduction in the WM composite within MC that was independent of vascular changes (white matter hyperintensities), and age. Hyperphosphorylation of CSF tau at other sites and total tau did not significantly predict WM composite loss.

conclusionsWe identified a site-specific relationship between CSF phosphorylated tau and WM decline within MC. The presence of both amyloid deposition and Tau phosphorylation at pT205 were associated with WM composite loss. These findings highlight a primary AD-specific mechanism for WM dysfunction that is tightly coupled to symptom manifestation and cognitive decline.

Indexed as

Alzheimer DiseaseCognitive DysfunctionWhite MatterAmyloid beta-PeptidesBiomarkersDiffusion Tensor ImagingHumansPhosphorylationtau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsADADCSFPCAPhosphorylated tauWhite matter

Identifiers

PMID35358703
PMCPMC9701560
OpenAlexW4220852854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.